INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2016-12-16
Target enrollment:
Participant gender:
Summary
A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy
and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or
refractory Hodgkin Lymphoma.